Genomic sequencing Assessment of 733 HER2-amplified primary and metastatic breast tumours unveiled substantial enrichment of mutations that activate RAS–MAPK signalling in Innovative tumours addressed with prior anti-HER2 therapies121. These mutations, which include NF1 and HER2 activating mutations, add to resistance to tucatinib and neratinib. Expressing your feelings. Discover an a... https://www.directivepublications.org/journal-of-clinical-breast-cancer/